Carriage Services Announces Strong Third Quarter Results and Confirms the Midpoint of the 2025 Outlook
Globenewswire· 2025-11-06 05:47
核心财务表现 - 第三季度调整后稀释每股收益为0.75美元,较去年同期的0.64美元增长17.2% [3] - 第三季度总营业收入为1.027亿美元,较去年同期的1.007亿美元增长2.0% [6][7] - 第三季度运营收入为1750万美元,运营利润率为17.0%,去年同期分别为2290万美元和22.7% [6] - 第三季度调整后 consolidated EBITDA 为3298万美元,调整后 consolidated EBITDA 利润率为32.1%,去年同期分别为3074万美元和30.5% [8][17] 业务板块驱动因素 - 墓地预需求销售强劲增长,第三季度同比增长21.4%,推动运营收入增长5.2% [5][7] - 金融服务收入第三季度同比增长27.2%,主要受预需求保险合同销售增长27.9%的推动 [7] - 第三季度售出的预需求墓穴权益平均价格为6257美元,较去年同期的5360美元增长15.1% [6][7] - 第三季度殡葬合同平均收入为5651美元,较去年同期的5540美元增长2.0% [8] 战略举措与资本配置 - 本季度完成了对两家年收入超过1500万美元企业的战略性收购,这些企业去年服务了超过2600个家庭 [4] - 同时剥离了非核心资产,包括七家殡仪馆和一处墓地,以将资本重新配置到更好的长期价值创造机会上 [4][7] - 通过资产剥离和运营改善,杠杆比率降至4.1倍 [7] - 公司重申进入增长模式,通过战略性收购扩大业务版图 [4] 运营指标与趋势 - 第三季度合并预需求墓穴权益(财产)销售数量同比增长1.7%,合并平均售价同比增长16.7% [11] - 第三季度合并殡葬合同数量同比下降5.5%,但合并平均每份合同收入同比增长2.0% [11] - 火化率持续上升,第三季度合并火化率为61.3%,高于去年同期的60.7% [8] - 前九个月净收入为3920万美元,较去年同期的2310万美元增长1610万美元 [11] 2025年业绩展望 - 修订后的2025年全年总收入预期为4.13亿至4.17亿美元 [12] - 修订后的调整后稀释每股收益预期为3.25至3.30美元 [12] - 修订后的调整后 consolidated EBITDA 预期为1.30亿至1.32亿美元 [12] - 修订后的调整后自由现金流预期为4400万至4800万美元 [12]
National Fuel Reports Fourth Quarter and Full Year Fiscal 2025 Earnings
Globenewswire· 2025-11-06 05:45
WILLIAMSVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- National Fuel Gas Company (“National Fuel” or the “Company”) (NYSE:NFG) today announced consolidated results for the three months and fiscal year ended September 30, 2025. FOURTH QUARTER FISCAL 2025 SUMMARY GAAP earnings per share of $1.18 compared to a net loss of $1.84 per share in the prior year.Adjusted earnings per share of $1.22, an increase of 58%, compared to $0.77 per share in the prior year. See non-GAAP reconciliation on page 2.Announced the ...
Citizens Business Bank Expands with De Novo Office in Temecula-Murrieta Region
Globenewswire· 2025-11-06 05:45
Ontario, CA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Citizens Business Bank announced the opening of a new Loan Production Office in Temecula, California. The new location is led by Leonard Barbosa, Vice President and Center Manager, who brings more than 35 years of banking experience in Southern California. Barbosa has assembled a team of seasoned local bankers to serve the Temecula-Murrieta market. “This strategic expansion strengthens our presence in the rapidly growing Temecula-Murrieta region of Riverside C ...
W&T Offshore Announces Third Quarter 2025 Results and Declares Dividend for Fourth Quarter of 2025
Globenewswire· 2025-11-06 05:45
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- W&T Offshore, Inc. (NYSE: WTI) (“W&T,” the “Company,” “we” or “us”) today reported operational and financial results for the third quarter of 2025 and declared a fourth quarter 2025 dividend of $0.01 per share. This press release includes non-GAAP financial measures, including Adjusted Net Loss, Adjusted EBITDA, Free Cash Flow and Net Debt, which are described and reconciled to the most comparable GAAP measures in the accompanying tables to this press release under ...
Rocket Lab Successfully Deploys Sixth Earth-Imaging Satellite for iQPS
Globenewswire· 2025-11-06 05:45
Live broadcast of Rocket Lab's 74th launch and sixth for iQPS. LONG BEACH, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today successfully launched its 74th Electron mission and deployed the latest satellite to orbit for Institute for Q-shu Pioneers of Space, Inc. (iQPS). The mission was Rocket Lab’s sixth dedicated mission for iQPS, making Rocket Lab the most prolific launcher o ...
Benitec Biopharma Inc. Announces Proposed Public Offering
Globenewswire· 2025-11-06 05:43
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and intends to conduct a concurrent regis ...
Monroe Capital Corporation BDC Announces Third Quarter 2025 Results
Globenewswire· 2025-11-06 05:35
CHICAGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (NASDAQ: MRCC) today announced its financial results for the third quarter ended September 30, 2025. Except where the context suggests otherwise, the terms “Company,” “we,” “us,” and “our” refer to Monroe Capital Corporation (together with its subsidiaries). Third Quarter 2025 Financial Highlights Net Investment Income ("NII") of $1.8 million, or $0.08 per shareAdjusted Net Investment Income (a non-GAAP measure described below) of $1.9 mi ...
Arq Reports Third Quarter 2025 Results
Globenewswire· 2025-11-06 05:33
Generated revenue of $35 million, driven by strong performance of the foundational PAC business Reported Adjusted EBITDA of $5.2 million, achieving sixth consecutive quarter of positive Adjusted EBITDA Achieved 7% price increase year-over-year Achieved initial commercial phase GAC production and sales GREENWOOD VILLAGE, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purif ...
MKS Inc. Reports Third Quarter 2025 Financial Results
Globenewswire· 2025-11-06 05:30
Revenue of $988 million, at the high end of guidance GAAP net income of $74 million and net income per diluted share of $1.10, each in the upper half of guidanceAdjusted EBITDA of $240 million and Non-GAAP net earnings per diluted share of $1.93, each in the upper half of guidanceOperating cash flow of $197 million and free cash flow of $147 million, enabling continued focus on the prepayment of debt and reducing net leverage ratio to 3.9x ANDOVER, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: ...
Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
Globenewswire· 2025-11-06 05:30
Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss onlyBody mass index (BMI) and waist-to-height ratio (a measurement of unhealthy waist size) represent important obesity treatment targets, associated with a lower risk of obesity-related complicationsA study of people with obesity (STEP UP trial) showed that more people taking Wegovy® achieved a BMI under 27 and a waist-to-height ratio of less than 0.53, compared to non ...